Amgen Inc. reaffirmed revenue guidance for the year 2022. The company reaffirmed going to 2022 revenue ranges despite by headwinds.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
308.8 USD | -0.21% | -3.02% | +7.43% |
05-22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
05-22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.43% | 166B | |
+37.74% | 723B | |
+34.26% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.23% | 244B | |
+9.70% | 208B | |
-4.79% | 205B | |
+2.81% | 168B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen Inc. Reaffirms Revenue Guidance for the Year 2022